

Topic: Health Canada and International Collaboration Initiatives (i.e., ORBIS, ACCESS, etc.)

Dr. Maxime Sasseville is manager of Oncology within Health Canada and his team of scientific and clinical evaluators is responsible for pre-market drug risk/benefit assessment for drugs for the treatment of haematological and oncological diseases.

Dr. Sasseville has 15 years of experience in the regulatory and scientific evaluation of new drugs in different therapeutic areas including oncology, metabolism and reproduction.

He is also part of a number of initiatives for Health Canada related to improving Patient-Reported Outcomes use in regulatory decisions [SISAQOL Consortium and PROTEUS Consortium] or to foster international collaboration among regulatory agencies [ACCESS and ORBIS].



Dr. Maxime Sasseville,
MSc PhD
Manager, Oncology Division 2,
PDD, Health Canada